Dr. Rodger Novak
Dr. Rodger Novak co-founded CRISPR Therapeutics together with Emmanuelle Charpentier and Shaun Foy in November 2013, and has served as a Director on our Board of Directors since inception. He served as our Chief Executive Officer until December 2017 and since December 2017, as our President and Chairman. Rodger is an experienced biotechnology and pharmaceutical executive, and former Professor of Microbiology at the Vienna Biocenter in Austria. He brings a combination of scientific experience gained through his academic career and a proven track record of successfully translating technologies into pharmaceutical products. Before co-founding our company, Rodger served as Global Head of Anti-Infectives Research & Development at Sanofi. Prior to Sanofi, he co-founded Nabriva Therapeutics and served as Chief Operating Officer for almost six years. He started his pharmaceutical career at Sandoz (Novartis), where he served as the Deputy Head of the Antibiotic Research Institute. Rodger received an M.D. from Philipps University of Marburg, Germany. He continued with post-doctoral work in New York City at The Rockefeller University, St. Jude Children’s Research Hospital and the Skirball Institute of Biomolecular Medicine at NYU Langone Medical Center. Rodger has authored numerous publications, including articles in Nature, Nature Medicine and Molecular Cell, and is also a co-inventor of five patents.
You are now leaving the CRISPR Therapeutics website.
CRISPR Therapeutics is not responsible for the content or availability of third-party sites.